

***$\beta$* -STRAND MIMICRY AS THE BASIS FOR A  
UNIVERSAL APPROACH TO PROTEASE  
INHIBITION**

---

A thesis  
submitted in fulfilment of the  
requirements for the degree of  
**Doctor of Philosophy in Chemistry**  
at  
The University of Adelaide  
School of Chemistry and Physics  
By  
**Seth Adam Jones**



June 2011

Abstract.....	vi
Declaration and Published Works .....	ix
Acknowledgements .....	xi
Abbreviations .....	xii
1 Introduction.....	2
1.1 Peptidomimetics.....	2
1.2 Biologically active macrocycles from nature .....	3
1.3 Synthetic examples of biologically active macrocycles .....	6
1.4 Macrocyclisation strategies.....	8
1.5 Olefin metathesis .....	10
1.5.1 Historical development of olefin metathesis catalysts .....	10
1.5.2 Metathesis mechanism.....	12
1.5.3 Development of single component metathesis catalysts .....	13
1.5.4 Grubbs' metathesis catalysts .....	14
1.5.5 RCM in the preparation of rationally designed biologically active compounds	19
1.5.6 RCM in natural product synthesis .....	19
1.6 Proteases as targets for peptidomimetic design.....	21
1.6.1 The importance of $\beta$ -strand mimicry in protease ligands.....	22
1.7 Calpain.....	23
1.8 HIV Protease.....	25
1.8.1 HIV and AIDS.....	27

1.8.2	HIV genome and structure .....	29
1.8.3	HIV life cycle .....	29
1.8.4	Development of HIV Protease inhibitors .....	30
1.8.5	First generation HIV Protease inhibitors .....	34
1.8.6	Second generation HIV Protease inhibitors .....	34
1.9	Research described in this thesis .....	36
1.10	References.....	37
2	Synthesis and testing of acyclic calpain inhibitors .....	48
2.1	Survey of acyclic calpain inhibitors .....	49
2.1.1	Inhibitor warhead .....	49
2.1.2	Effects of P1 and P2 residues on inhibitor activity .....	53
2.1.3	Effect of <i>N</i> -capping groups on potency in peptidic calpain inhibitors.....	56
2.2	<i>N</i> -heterocyclic peptidic calpain inhibitors .....	58
2.3	Aim of the study presented here .....	61
2.4	<i>In silico</i> modelling .....	62
2.5	Synthesis of the target compounds .....	65
2.6	Results and discussion .....	68
2.7	Conclusion .....	71
2.8	References.....	72
3	Design and synthesis of a macrocyclic $\beta$ -strand mimetic for incorporation into calpain and HIV protease inhibitors .....	76
3.1	Macrocyclic inhibitors of HIV protease and calpain.....	76

3.2	Design of the macrocyclic $\beta$ -strand mimic 3.8 for incorporation into potential calpain and HIV protease inhibitors .....	80
3.3	Preparation of 3.8.....	83
3.3.1	Synthesis of 3.8 .....	84
3.3.2	Effect of reaction conditions on the ring closing metathesis of diene 3.14.....	86
3.4	Attempted RCM of 3.24 using aqueous metathesis.....	90
3.5	Conclusion .....	91
3.6	References.....	92
4	Synthesis and testing of the calpain inhibitors 3.9 and 3.10 .....	96
4.1	Synthesis of 3.9.....	96
4.2	Synthesis of 3.10.....	97
4.3	<i>In vitro</i> testing of potential inhibitors against m-calpain and proteasome 20S .....	100
4.3.1	Discussion.....	102
4.4	Conclusion and future work.....	104
4.5	References.....	107
5	Synthesis of macrocyclic HIV Protease inhibitors.....	110
5.1	Synthetic strategy for the preparation of 3.11 and 3.12.....	111
5.2	Synthesis of key building blocks 5.1 – 5.4 .....	112
5.2.1	Preparation of 5.1a.....	112
5.2.2	Preparation of 5.2a.....	114
5.2.3	Preparation of 5.3, 5.4a and 5.4b.....	118
5.3	Preparation of macrocyclic HIV Protease inhibitors .....	121

5.3.1	Attempted synthesis of 3.12a by reaction of ( <i>S,S</i> )-epoxide 5.1a and macrocyclic amine 3.8.....	121
5.3.2	Attempted synthesis of 3.12a by RCM of 5.15 .....	123
5.3.3	Attempted synthesis of 3.12a from 5.20.....	126
5.3.4	Successful synthesis of macrocyclic HIV Protease inhibitors 3.11 and 3.12b via reductive amination.....	129
5.4	<i>In vitro</i> testing of potential inhibitors against HIV-1 protease and XMRV protease... ..	133
5.4.1	Discussion .....	135
5.5	Conclusion and future work.....	136
5.6	References.....	138
6	Macrocyclic synthesis by cross-metathesis.....	142
6.1	Introduction.....	142
6.1.1	Examples of cross-metathesis in natural product synthesis .....	144
6.1.2	Methodologies for selective cross-metathesis.....	146
6.2	Synthesis of the macrocycle 6.1 .....	150
6.2.1	Synthesis of the olefins 6.5, 6.6, 6.23, and 6.24.....	150
6.2.2	Cross-metathesis of 6.5 and 6.24, and the synthesis of 6.1 .....	153
6.3	Other CM routes to 6.4 .....	156
6.3.1	Synthesis of 6.4 .....	161
6.4	Conclusion.....	163
6.5	References.....	166

7	Large scale synthesis of CAT0811 .....	170
7.1	Synthesis of $\beta$ -strand macrocyclic templates by ring closing metathesis.....	170
7.1.1	Optimised synthesis of CAT0811 by ring closing metathesis.....	172
7.2	Efforts towards large scale CAT0811 synthesis .....	174
7.2.1	CAT0811 synthesis through macrolactamisation.....	181
7.3	Conclusion .....	183
7.4	References.....	184
8	Experimental .....	188
8.1	General methods and experimental procedures .....	188
8.2	Experimental described in Chapter 2.....	199
8.3	Experimental described in Chapter 3.....	211
8.4	Experimental described in Chapter 4.....	221
8.5	Experimental described in Chapter 5.....	229
8.6	Experimental described in Chapter 6.....	248
8.7	Experimental described in Chapter 7.....	256
8.8	References.....	263
A1	Calpain inhibition assay .....	267
A2	HPLC analysis of cross-metathesis mixtures .....	271

## Abstract

This thesis describes the design, preparation, and testing of a range of protease inhibitors.

**Chapter One** introduces the concept of peptidomimetics, and discusses how proteases almost universally bind their ligands in a  $\beta$ -strand conformation. The idea of constraining a compound into a biologically active conformation by the introduction of a ring or bridge is discussed. The technique of ring closing metathesis as a strategy for macrocyclisation is introduced. The chapter also discusses calpain and HIV proteases and their structures and implications in human disease.

**Chapter Two** surveys the acyclic calpain inhibitors reported in the literature. A series of *N*-heterocyclic peptidic calpain inhibitors were docked *in silico* into an ovine m-calpain homology model using Glide, which revealed that compounds **2.60** – **2.67** all adopted a  $\beta$ -strand conformation upon binding. The modelling revealed low energy conformations of **2.60**, **2.61** and **2.66** not in a  $\beta$ -strand geometry. The synthesis and testing of these inhibitors is described, with **2.63** displaying an  $IC_{50}$  of 40 nM against m-calpain in an *in vitro* assay.

**Chapter Three** describes the design and synthesis of the  $\beta$ -strand mimic macrocycle **3.8**, which was prepared using ring closing metathesis. The chapter also describes the design of a number of calpain and HIV protease inhibitors that incorporate **3.8**. Each inhibitor is designed to bind and inhibit a specific protease target.

**Chapter Four** describes the synthesis and testing of a series of macrocyclic calpain and proteasome 20S inhibitors. The preparation of the aldehydes **3.9** and **3.10** by elaboration of the macrocycle **3.8** is described. As well, the preparation of **3.10** from the *N*-capped 4-fluorosulphonyl diene **4.4** is described. The most potent macrocycle in the series was **3.10**, which displays an  $IC_{50}$  against m-calpain of 2000 nM, and an  $IC_{50}$  against the chymotrypsin like activity of proteasome 20S of 2 nM.

**Chapter Five** describes the synthesis of a series of building blocks, and their use in the attempted preparation of the potential HIV protease inhibitor **3.12a**, as well as the successful preparation of the potential HIV protease inhibitors **3.11** and **3.12b**. Preliminary studies testing the biological activity of compounds **3.11**, **3.12b** and **5.21** found that they displayed a percentage inhibition of HIV-1 subtype B protease of 86, 63, and 26%, respectively. The  $K_i$  of **3.11** against HIV-1 subtype B protease was also determined to be 62 nM. The activity of **3.11** against HIV-1 protease establishes that the common macrocyclic core **3.8** can be incorporated into inhibitors of both calpain, and HIV-1 protease.

**Chapter Six** describes the preparation of a key macrocycle by cross-metathesis. The preparation of **6.4** by cross-metathesis of the olefins **6.5** and **6.24** is described, as well as the elaboration of **6.4** to give the macrocycle **6.1**. A systematic study of the cross-metathesis of the olefins **6.5**, **6.6**, **6.23** and **6.24** is described. Their percentage conversion to **6.4** was calculated using high performance liquid chromatography analysis. The highest conversion to **6.4** was found to be 60%, from the cross metathesis of an equimolar mixture of **6.6** and **6.23**.



**Chapter Seven** describes a multi-gram synthesis of the potent macrocyclic calpain inhibitor **CAT0811**. The key step in the synthesis is the base induced macrocyclisation of the iodopeptide **7.10** to give **7.6**. The macrocycle **7.6** was also prepared by macrolactamisation of the pseudopeptide **7.9**. The synthesis was found to be scalable, affordable and efficient, and removes the need for Grubbs' 2nd generation catalyst (**II**).

## **Declaration and Published Works**

This work contains no material which has been accepted for the award of any other degree or diploma in any other university or tertiary institution to Seth Jones and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I also acknowledge that copyright of published works contained within this thesis (as listed below) resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital repository, the Library catalogue, the Australasian Digital Thesis Program (ADPT) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Seth Jones

Date:

Work in this thesis has appeared in the following publications:

“*N*-Heterocyclic Dipeptide Aldehyde Calpain Inhibitors”, Jones, S. A.; Jones, M. A.; McNabb, S. B.; Aitken, S. G.; Coxon, J. M.; Abell, A. D. *Protein Pept. Lett.* **2009**, *16*, 1466-1472.

“Efficient Large-Scale Synthesis of CAT811, a Potent Calpain Inhibitor of Interest in the Treatment of Cataracts”, Jones, M. A.; Coxon, J. M.; McNabb, S. B.; Mehrrens, J. M.; Alexander, N. A.; Jones, S.; Chen, H.; Buisan, C.; Abell, A. D. *Aust. J. Chem.* **2009**, *62*, 671-675.

## Acknowledgements

Thank you to Professor Andrew Abell for his guidance and supervision throughout my PhD. I am especially thankful for the time and energy he has put into revising and guiding me on writing this thesis. I would also like to thank Professor Jim Coxon for his invaluable guidance and advice from when I was at the University of Canterbury.

I would also like to acknowledge the help of the many post doctoral fellows and senior PhD students who have helped guide me through my studies. In particular I would like to thank Dr Matthew Jones, Dr Steve Aitken, Dr Stephen McNabb, Dr James Gardiner, Dr Markus Pietsch, and Dr Steven Ballet.

A big thanks must also go to those that have helped me with my research, especially Dr Matthew Jones, Dr Markus Pietsch, and Dr Janna Mehrrens who conducted the calpain inhibition assays for me; Dr Paul Nielson and Limei Sieu for the proteasome 20S assays they did; and Dr Stephen McNabb for the molecular modelling studies. As well I'd like to thank Professor Ben Dunn and Nathan Goldfarb from the University of Florida for conducting the HIV protease and XMRV protease assay. I would also like to thank all the technical staff at the University of Canterbury, and University of Adelaide for all their help over the years.

Finally, I would like to thank all my family and friends for their support and love during my studies. I would not have been able to achieve this without them.

## Abbreviations

18-crown-6	1,4,7,10,13,16-hexaoxacyclooctadecane
aq	aqueous
AIDS	Acquired Immunodeficiency Syndrome
Boc	<i>tert</i> -butoxycarbonyl
br	broad (spectroscopic)
calcd	calculated
Cbz	benzyloxycarbonyl
CM	cross-metathesis
conc	concentrated
Cy	cyclohexyl
DCM	dichloromethane
DDQ	2,3-dichloro-5,6-dicyano-1,4-benzoquinone
DIPEA	N,N-diisopropylethylamine
DMF	dimethylformamide
DMSO	dimethyl sulphoxide
EDC	1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride
equiv	equivalent

ESI	electrospray ionisation
Et	ethyl
FTIR	Fourier transform infrared
h	hour(s)
HAART	highly active antiretroviral therapy
HATU	2-(7-aza-1 <i>H</i> -benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HIV	Human Immunodeficiency Virus
HOAt	1-hydroxy-7-azabenzotriazole
HOBt	1-hydroxybenzotriazole
HPLC	high-performance liquid chromatography
HRMS	high-resolution mass spectrometry
iPA	isopropylalcohol
IR	infrared
lit.	literature value
Me	methyl
min	minute(s)
mp	melting point
Ms	methylsulphonyl (mesyl)
MS	mass spectrometry
<i>m/z</i>	mass-to-charge ratio
NHC	<i>N</i> -heterocyclic carbene
NMR	nuclear magnetic resonance
PB	4-phenylbutyryl-

PDB	Protein Data Bank
Ph	phenyl
PI	protease inhibitor(s)
ppm	part(s) per million
Pr	propyl
PTC	phase transfer catalyst
PTSA	<i>p</i> -toulenesulphonic acid
Py	pyridine
quant	quantitative
RCM	ring closing metathesis
ROM	ring-opening metathesis
ROMP	ring-opening metathesis polymerisation
rt	room temperature
SAR	structure activity relationship
spec	spectrometry
TBAB	tetrabutylammonium bromide
TBAI	tetrabutylammonium iodide
TCE	1,1,2-trichloroethane
TEA	triethylamine
temp	temperature
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography

Ts	<i>para</i> -toluenesulphonyl (tosyl)
UV	ultraviolet
v/v	volume per unit volume
w/w	weight per unit weight